Google’s AI outperforms humans in detecting breast cancer

Google’s DeepMind AI system is better at detecting breast cancer than human experts, according to a new study published in Nature.

The findings could help propel more accurate screening results, as the interpretation of mammograms has been subject to false positives and false negatives, according to the researchers from Google Health.

The study included a large-scale dataset of 25,856 mammograms from women in the U.K. and 3,097 mammograms from U.S. women to train the AI system. The system was tested against mammograms of women who had breast cancer or normal follow-up images a year later.

The AI system outperformed both the historical decisions made by radiologists who assessed the mammograms and the decisions of six expert radiologists who interpreted 500 randomly selected cases in the study.

“The area under the receiver operating characteristic curve (AUC-ROC) for the AI system was greater than the AUC-ROC for the average radiologist by an absolute margin of 11.5%,” first author Scott Mayer McKinney, of Google Health, and colleagues wrote in Nature.

The AI system led to a 5.7% and 1.2% reduction in false positives in U.S. and U.K mammograms, respectively. It also had a 9.4% and 2.7% reduction in false negatives.

The findings could help AI detect breast cancer in the future.

“This robust assessment of the AI system paves the way for clinical trials to improve the accuracy and efficiency of breast cancer screening,” McKinney et al. wrote.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.